- Profound Medical (PRN) provides TULSA-PRO reimbursement update
- The current application for TULSA has been withdrawn for consideration at the upcoming September 2022 Editorial Panel Meeting
- An updated application, which will include 2022 utilization data, will be submitted at the appropriate time in 2023
- CMS released its proposed OPPS reimbursement rule for 2023
- The proposed rule would increase reimbursement to a hospital billing under C9734 by approximately 5 per cent to $13,274
- Profound Medical (PRN) is down 4.20 percent, trading at C$8.67 at 1:55 pm EST
Profound Medical (PRN) has given a U.S. reimbursement update for Transurethral Ultrasound Ablation performed with its TULSA-PRO system.
The current application for TULSA has been withdrawn for consideration at the upcoming September 2022 Editorial Panel Meeting.
An updated application, including 2022 utilization data, will be submitted at the appropriate time in 2023.
In the meantime, U.S. hospitals performing the TULSA procedure on Medicare patients generally utilize an existing temporary ‘C’ code established by the U.S. Centers for Medicare and Medicaid Services for the Hospital Outpatient Prospective Payment System.
In July 2022, CMS released its proposed OPPS reimbursement rule for 2023.
The proposed rule would increase reimbursement to a hospital billing under C9734 by approximately 5 per cent to $13,274.
Comments on the proposed rule are due by the end of September and, once finalized, the policies and payment rates in the final rule will take effect on January 1, 2023.
“We believe that the proposed hospital payment under C9734 is sufficient to help further advance the adoption of the technology in the near- to mid-term in the United States,” said Arun Menawat, CEO and Chairman of Profound.
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound Medical (PRN) is down 4.20 percent, trading at C$8.67 at 1:55 pm EST.
